Eyepoint Pharmaceuticals Inc (EYPT) Stock Price, Quote & News

Company Profile

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 926 5000

Fax: 617 926 5050

Website: eyepointpharma.com

Address:

480 Pleasant Street, Suite A-210, Watertown, United States

biostock Jun. 17 at 3:27 PM

$EYPT $SPRO $SGMT $NUVB $XBI

1 · Reply

biostock Jun. 17 at 3:01 PM

$EYPT $SRPO $SGMT $QQQ $SPY

0 · Reply

biostock Jun. 17 at 2:02 PM

$EYPT $28 RBC Capital Target. $XBI $QQQ $SPY

0 · Reply

G101SPM Jun. 17 at 11:11 AM

$EYPT $8.95 bid. DAC (2) 6.93 / last $5.48 (2.25.24) EXIT $13.50. BRIEF: RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target.

0 · Reply

daviscupper Jun. 13 at 6:53 PM

$EYPT Another Healthcare Conference in 12-days. We will trend up into it starting next week. Cheers and Glta.

1 · Reply

biostock Jun. 13 at 4:09 PM

$EYPT $SGMT $SPRO $SPY $QQQ

1 · Reply

biostock Jun. 12 at 5:45 PM

$SGMT Woop Woop $SPRO $EYPT next. $QQQ $SPY

0 · Reply

rizzato Jun. 12 at 1:47 PM

$EYPT why we are falling down again?

1 · Reply

Poet5 Jun. 12 at 1:23 AM

$EYPT If they bring it back down to 6-7.50 agsin that’s nice but its so F absurd to point of completely ridculous. This should be sitting at 11-12.

0 · Reply

rizzato Jun. 10 at 10:28 PM

$EYPT any news from the Goldman Sachs Healthcare Conference?

0 · Reply

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jun 12, 2025, 11:03 AM EDT - 5 days ago

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

May 28, 2025, 4:01 PM EDT - 20 days ago

EyePoint Announces Participation at Upcoming Investor Conferences

May 27, 2025, 7:00 AM EDT - 21 days ago

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

May 16, 2025, 7:00 AM EDT - 4 weeks ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 7, 2025, 2:49 PM EDT - 5 weeks ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 5 weeks ago

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Apr 30, 2025, 7:00 AM EDT - 6 weeks ago

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 27, 2025, 7:00 AM EDT - 2 months ago

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 5, 2025, 2:51 PM EST - 3 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 7:00 AM EST - 3 months ago

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

Feb 26, 2025, 7:00 AM EST - 3 months ago

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

Feb 25, 2025, 7:00 AM EST - 4 months ago

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 12:39 PM EST - 4 months ago

EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival

Jan 30, 2025, 7:00 AM EST - 4 months ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 8, 2025, 7:00 AM EST - 5 months ago

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

Dec 4, 2024, 7:00 AM EST - 6 months ago

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

Nov 14, 2024, 5:04 AM EST - 7 months ago

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 4, 2024, 7:00 AM EST - 8 months ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Oct 31, 2024, 4:00 PM EDT - 8 months ago

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Oct 29, 2024, 9:47 PM EDT - 8 months ago

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

Oct 28, 2024, 5:14 PM EDT - 8 months ago

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 7:00 AM EDT - 8 months ago

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

Oct 24, 2024, 7:00 AM EDT - 8 months ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

Sep 4, 2024, 7:00 AM EDT - 10 months ago

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

Aug 29, 2024, 5:35 PM EDT - 10 months ago

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 8, 2024, 7:00 AM EDT - 11 months ago

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Jun 18, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Jun 5, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

May 7, 2024, 12:50 PM EDT - 1 year ago

EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program

May 6, 2024, 9:10 AM EDT - 1 year ago

EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal

May 6, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

Apr 2, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

Mar 7, 2024, 12:29 PM EST - 1 year ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript

Mar 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

Mar 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

Feb 29, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024

Feb 21, 2024, 8:36 AM EST - 1 year ago

EyePoint Is Betting The Bank On EYP-1901

Feb 3, 2024, 4:20 PM EST - 1 year ago

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Jan 31, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 10, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema

Dec 20, 2023, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 7:55 AM EST - 1 year ago

EyePoint (EYPT) stock price went parabolic: brace for a pullback

Dec 4, 2023, 5:06 PM EST - 1 year ago

EyePoint announces $175 million stock offering following record surge in share price

Dec 4, 2023, 7:40 AM EST - 1 year ago

EyePoint Pharmaceuticals' stock soars 362% after company announces positive data from trial of wet AMD treatment

AMD

Dec 4, 2023, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints

Nov 1, 2023, 1:03 PM EDT - 1 year ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call Transcript

Nov 1, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments

Oct 31, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023

biostock Jun. 17 at 3:27 PM

$EYPT $SPRO $SGMT $NUVB $XBI

1 · Reply

biostock Jun. 17 at 3:01 PM

$EYPT $SRPO $SGMT $QQQ $SPY

0 · Reply

biostock Jun. 17 at 2:02 PM

$EYPT $28 RBC Capital Target. $XBI $QQQ $SPY

0 · Reply

G101SPM Jun. 17 at 11:11 AM

$EYPT $8.95 bid. DAC (2) 6.93 / last $5.48 (2.25.24) EXIT $13.50. BRIEF: RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target.

0 · Reply

daviscupper Jun. 13 at 6:53 PM

$EYPT Another Healthcare Conference in 12-days. We will trend up into it starting next week. Cheers and Glta.

1 · Reply

biostock Jun. 13 at 4:09 PM

$EYPT $SGMT $SPRO $SPY $QQQ

1 · Reply

biostock Jun. 12 at 5:45 PM

$SGMT Woop Woop $SPRO $EYPT next. $QQQ $SPY

0 · Reply

rizzato Jun. 12 at 1:47 PM

$EYPT why we are falling down again?

1 · Reply

Poet5 Jun. 12 at 1:23 AM

$EYPT If they bring it back down to 6-7.50 agsin that’s nice but its so F absurd to point of completely ridculous. This should be sitting at 11-12.

0 · Reply

rizzato Jun. 10 at 10:28 PM

$EYPT any news from the Goldman Sachs Healthcare Conference?

0 · Reply

biostock Jun. 10 at 5:34 PM

$EYPT $SPRO The Squeeze awaits. $IWM $QQQ $SPY

2 · Reply

biostock Jun. 10 at 4:16 PM

$EYPT Billions in TAM. Short to cover Ratio 8.8 Days. $22 Coming $SPY $QQQ $IWM

0 · Reply

biostock Jun. 10 at 2:02 PM

$EYPT $22 Coming. Billions in TAM $XBI $QQQ $SPY

0 · Reply

daviscupper Jun. 9 at 7:11 PM

$EYPT Goldman Sachs Healthcare Conference could be quite illuminating. Lots of eyeballs on Eyepoint. Cheers and glta.

0 · Reply

daviscupper Jun. 9 at 4:30 PM

$EYPT Goldman Sachs’s Healthcare Conference tomorrow could offer some up to date details regarding our pivotal trials. Cheers and glta.

1 · Reply

biostock Jun. 9 at 1:19 PM

$EYPT $22 Coming. Billions in TAM. Short to cover ratio 8.8 Days.

0 · Reply

Ice_Wizard Jun. 7 at 2:38 PM

$EYPT channel breakout

0 · Reply

rizzato Jun. 6 at 9:02 PM

$EYPT now we really need just the confirmation that everything is proceeding in the right direction and we will see the moon

0 · Reply

topstockalerts Jun. 6 at 4:58 PM

$EYPT buyers stepping in.. ✅✅

0 · Reply

biostock Jun. 6 at 4:26 PM

$EYPT $SGMT $SPRO All aboard The Squeeze Train. $SPY $QQQ

2 · Reply

SolNur Jun. 6 at 4:23 PM

$EYPT Quick context: EyePoint began dosing patients in the Phase 3 LUGANO trial in Oct 2024, and the LUCIA trial in Dec 2024. Given that DURAVYU (EYP-1901) is designed for twice-yearly injections, early patients are now likely receiving their second dose. While topline data is slated for 2026, EYPT might share preliminary data on how those patients did between now and end of the year.

2 · Reply

Ice_Wizard Jun. 6 at 3:58 PM

$EYPT bro, 107% tutes ownership? What?

0 · Reply

Market Cap	612.42M
Revenue (ttm)	43.27M
Net Income (ttm)	-130.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-302.45%
Debt to Equity Ratio	0.00

Volume	812,300
Avg Vol	839,328
Day's Range	N/A - N/A
Shares Out	68.81M
Stochastic %K	59%
Beta	1.61
Analysts	Strong Sell
Price Target	$29.50